185 related articles for article (PubMed ID: 37348919)
21. TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using
Minnix M; Li L; Yazaki PJ; Miller AD; Chea J; Poku E; Liu A; Wong JYC; Rockne RC; Colcher D; Shively JE
J Nucl Med; 2021 Jan; 62(1):55-61. PubMed ID: 32620701
[TBL] [Abstract][Full Text] [Related]
22. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
Heyerdahl H; Abbas N; Sponheim K; Mollatt C; Bruland Ø; Dahle J
Curr Radiopharm; 2013 Jun; 6(2):106-16. PubMed ID: 23551111
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Pagel JM; Kenoyer AL; Bäck T; Hamlin DK; Wilbur DS; Fisher DR; Park SI; Frayo S; Axtman A; Orgun N; Orozco J; Shenoi J; Lin Y; Gopal AK; Green DJ; Appelbaum FR; Press OW
Blood; 2011 Jul; 118(3):703-11. PubMed ID: 21613259
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
[TBL] [Abstract][Full Text] [Related]
27. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
[TBL] [Abstract][Full Text] [Related]
28. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
30. Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using α-Particle Radiation.
Shah MA; Zhang X; Rossin R; Robillard MS; Fisher DR; Bueltmann T; Hoeben FJM; Quinn TP
Bioconjug Chem; 2017 Dec; 28(12):3007-3015. PubMed ID: 29129050
[TBL] [Abstract][Full Text] [Related]
31. Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice.
Li HK; Morokoshi Y; Nagatsu K; Kamada T; Hasegawa S
Cancer Sci; 2017 Aug; 108(8):1648-1656. PubMed ID: 28514062
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis.
Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
Cancer Biother Radiopharm; 2000 Feb; 15(1):53-64. PubMed ID: 10740653
[TBL] [Abstract][Full Text] [Related]
33. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with
Bäck T; Chouin N; Lindegren S; Kahu H; Jensen H; Albertsson P; Palm S
J Nucl Med; 2017 Apr; 58(4):598-604. PubMed ID: 27688477
[TBL] [Abstract][Full Text] [Related]
34. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
35. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Green DJ; O'Steen S; Lin Y; Comstock ML; Kenoyer AL; Hamlin DK; Wilbur DS; Fisher DR; Nartea M; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; Orcutt KD; Wittrup KD; Press OW
Blood; 2018 Feb; 131(6):611-620. PubMed ID: 29158362
[TBL] [Abstract][Full Text] [Related]
36. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Seidl C; Zöckler C; Beck R; Quintanilla-Martinez L; Bruchertseifer F; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):312-22. PubMed ID: 21072513
[TBL] [Abstract][Full Text] [Related]
37. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
Green DJ; Orgun NN; Jones JC; Hylarides MD; Pagel JM; Hamlin DK; Wilbur DS; Lin Y; Fisher DR; Kenoyer AL; Frayo SL; Gopal AK; Orozco JJ; Gooley TA; Wood BL; Bensinger WI; Press OW
Cancer Res; 2014 Feb; 74(4):1179-89. PubMed ID: 24371230
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Koppe MJ; Oyen WJ; Bleichrodt RP; Verhofstad AA; Goldenberg DM; Boerman OC
Cancer Biother Radiopharm; 2006 Oct; 21(5):506-14. PubMed ID: 17105422
[TBL] [Abstract][Full Text] [Related]
39. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Park SI; Shenoi J; Pagel JM; Hamlin DK; Wilbur DS; Orgun N; Kenoyer AL; Frayo S; Axtman A; Bäck T; Lin Y; Fisher DR; Gopal AK; Green DJ; Press OW
Blood; 2010 Nov; 116(20):4231-9. PubMed ID: 20702781
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
